[开放获取]    白癜风诊疗共识（2024版）

doi:10.35541/cjd.20240260

Abstract

Abstract: 【Abstract】 Vitiligo is a common autoimmune skin disease, currently believed to be caused by autoreactive T cell-mediated destruction of melanocytes in the skin, mucous membranes, or hair follicles, which can significantly induce psychological distress in patients. The consensus on the diagnosis and treatment of vitiligo （2024 version） was formulated by the Pigmentary Disorder Group, Combination of Traditional and Western Medicine Dermatology, etc., based on the latest international research progress in the diagnosis and treatment of vitiligo and actual situation in China. This version of consensus highlights early intervention, integrative therapy, application of JAK inhibitors in vitiligo, and provides future research directions, aiming to guide the treatment of vitiligo.

Key words: Vitiligo, Diagnosis, Therapy, Phototherapy, Early intervention, JAK inhibitors, Expert consensus

Pigmentary Disorder Group, Combination of Traditional and Western Medicine Dermatology, Research Center for Vitiligo, Chinese Society of Dermatology, Committee on Pigmentation Disorders, China Dermatologist Association . Consensus on the diagnosis and treatment of vitiligo （2024 version）[J]. Chinese Journal of Dermatology, 2024, 57(12): 1065-1070.doi:10.35541/cjd.20240260

References ［31］

［1］	中国中西医结合学会皮肤性病专业委员会色素病学组. 白癜风诊疗共识（2021版）［J］. 中华皮肤科杂志, 2021,54（2）:105⁃109. doi: 10.35541/cjd.20200785.
［2］	van Geel N, Passeron T, Wolkerstorfer A, et al. Reliability and validity of the Vitiligo Signs of Activity Score （VSAS）［J］. Br J Dermatol, 2020,183（5）:883⁃890. doi: 10.1111/bjd.18950.
［3］	Speeckaert R, Speeckaert M, De Schepper S, et al. Biomarkers of disease activity in vitiligo: a systematic review［J］. Autoimmun Rev, 2017,16（9）:937⁃945. doi: 10.1016/j.autrev. 2017.07.005.
［4］	Goh BK, Pandya AG. Presentations, signs of activity, and differential diagnosis of vitiligo［J］. Dermatol Clin, 2017,35（2）:135⁃144. doi: 10.1016/j.det.2016.11.004.
［5］	Xiang W, Xu A, Xu J, et al. In vivo confocal laser scanning microscopy of hypopigmented macules: a preliminary comparison of confocal images in vitiligo, nevus depigmentosus and postinflammatory hypopigmentation［J］. Lasers Med Sci, 2010,25（4）:551⁃558. doi: 10.1007/s10103⁃010⁃0764⁃2.
［6］	Ibrahim S, Hegazy RA, Gawdat HI, et al. Differentiating active from stable vitiligo: the role of dermoscopic findings and their relation to CXCL10［J］. J Cosmet Dermatol, 2022,21（10）:4651⁃4658. doi: 10.1111/jocd.14922.
［7］	Bae JM, Oh SH, Kang HY, et al. Development and validation of the Vitiligo Extent Score for a Target Area （VESTA） to assess the treatment response of a target lesion［J］. Pigment Cell Melanoma Res, 2019,32（2）:315⁃319. doi: 10.1111/pcmr.12730.
［8］	Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV⁃B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index［J］. Arch Dermatol, 2004,140（6）:677⁃683. doi: 10.1001/archderm.140. 6.677.
［9］	Komen L, da Graça V, Wolkerstorfer A, et al. Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo［J］. Br J Dermatol, 2015,172（2）:437⁃443. doi: 10.1111/bjd.13432.
［10］	Chaweekulrat P, Silpa⁃Archa N, Apinuntham C, et al. Reliability, validity and feasibility of the Vitiligo Extent Score （VES） and Self⁃Assessment Vitiligo Extent Score （SA⁃VES） among vitiligo patients: a cross⁃cultural validation［J］. Clin Cosmet Investig Dermatol, 2021,14:949⁃957. doi: 10.2147/CCID.S324073.
［11］	Renert⁃Yuval Y, Ezzedine K, Grimes P, et al. Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients［J］. JAMA Dermatol, 2024,160（4）:453⁃461. doi: 10.1001/jamadermatol. 2024.0021.
［12］	Hu W, Xu Y, Ma Y, et al. Efficacy of the topical calcineurin inhibitors tacrolimus and pimecrolimus in the treatment of vitiligo in infants under 2 years of age: a randomized, open⁃label pilot study［J］. Clin Drug Investig, 2019,39（12）:1233⁃1238. doi: 10.1007/s40261⁃019⁃00845⁃x.
［13］	Al⁃Smadi K, Ali M, Alavi SE, et al. Using a topical formulation of vitamin D for the treatment of vitiligo: a systematic review［J］. Cells, 2023,12（19）:2387. doi: 10.3390/cells12192387.
［14］	Plachouri KM, Kyriakou G, Chourdakis V, et al. One stone, two birds: improvement of early⁃onset vitiligo under apremilast in a patient with plaque psoriasis［J］. Dermatol Ther, 2019,32（5）:e13064. doi: 10.1111/dth.13064.
［15］	Sun X, Sheng A, Xu AE. Successful treatment of vitiligo with crisaborole ointment: a report of two cases［J］. Br J Dermatol, 2023,188（3）:436⁃437. doi: 10.1093/bjd/ljac092.
［16］	Yuksel EP, Aydin F, Senturk N, et al. Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase⁃superoxide dismutase treatment in vitiligo patients［J］. Eur J Dermatol, 2009,19（4）:341⁃344. doi: 10.1684/ejd.2009.0699.
［17］	Hu W, Zhang L, Lin F, et al. Topical epigallocatechin⁃3⁃gallate in the treatment of vitiligo［J］. Australas J Dermatol, 2021,62（3）:e404⁃e407. doi: 10.1111/ajd.13612.
［18］	Lee J, Chu H, Lee H, et al. A retrospective study of methylprednisolone mini ⁃ pulse therapy combined with narrow band UVB in non⁃segmental vitiligo［J］. Dermatology, 2016,232（2）:224⁃229. doi: 10.1159/000439563.
［19］	Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review［J］. Front Immunol, 2021,12:790125. doi: 10.3389/fimmu.2021.790125.
［20］	Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial［J］. J Am Acad Dermatol, 2023,88（2）:395⁃403. doi: 10.1016/j.jaad.2022.11.005.
［21］	Su X, Luo R, Ruan S, et al. Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo［J］. J Am Acad Dermatol, 2023,89（6）:1257⁃1259. doi: 10.1016/j.jaad.2023.07.1016.
［22］	Phan K, Phan S, Shumack S, et al. Repigmentation in vitiligo using Janus kinase （JAK） inhibitors with phototherapy: systematic review and meta⁃analysis［J］. J Dermatolog Treat, 2022,33（1）:173⁃177. doi: 10.1080/09546634.2020.1735615.
［23］	Mohammad TF, Al⁃Jamal M, Hamzavi IH, et al. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo［J］. J Am Acad Dermatol, 2017,76（5）:879⁃888. doi: 10.1016/j.jaad.2016.12.041.
［24］	林洁, 樊奇敏, 许爱娥. 窄谱中波紫外线治疗白癜风平台期相关研究［J］. 临床皮肤科杂志, 2016,45（6）:465⁃468. doi: 10.16761/j.cnki.1000⁃4963.2016.06.025.
［25］	Zhang D, Wei X, Hong W, et al. A retrospective study of long term follow⁃up of 2283 vitiligo patients treated by autologous, non⁃cultured melanocyte⁃keratinocyte transplantation［J］. Aging （Albany NY）, 2021,13（4）:5415⁃5425. doi: 10.18632/aging.202472.
［26］	Seneschal J, Speeckaert R, Taïeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force⁃Part 2: specific treatment recommendations［J］. J Eur Acad Dermatol Venereol, 2023,37（11）:2185⁃2195. doi: 10.1111/jdv.19450.
［27］	Hu W, Lin F, Lei J, et al. Impacts of exposure to topical calcineurin inhibitors on metabolism in vitiligo infants［J］. Pediatr Res, 2023,93（3）:661⁃665. doi: 10.1038/s41390⁃022⁃02133⁃5.
［28］	Oiso N, Kawada A. Freckling promoted by topical tacalcitol in a Japanese boy with left eyelid vitiligo［J］. Pediatr Dermatol, 2012,29（5）:671⁃672. doi: 10.1111/j.1525⁃1470.2011.01559.x.
［29］	Chi CC, Wang SH, Kirtschig G. Safety of topical corticosteroids in pregnancy［J］. JAMA Dermatol, 2016,152（8）:934⁃935. doi: 10.1001/jamadermatol.2016.1009.
［30］	Mukhatayev Z, Le Poole IC. Vitiligo: advances in pathophysiology research and treatment development［J］. Trends Mol Med, 2024,30（9）:844⁃862. doi: 10.1016/j.molmed.2024.04.009.
［31］	Richmond JM, Strassner JP, Zapata L Jr, et al. Antibody blockade of IL⁃15 signaling has the potential to durably reverse vitiligo［J］. Sci Transl Med, 2018,10（450）:eaam7710. doi: 10.1126/scitranslmed.aam7710.

[1]	Zou Xianbiao, Chen Jinchun, Zeng Yue, Hao Yi. Application of ultrasonography in dermatology: progress and prospects [J]. Chinese Journal of Dermatology, 2024, 57(9): 785-790.
[2]	Xiang Xi, Zhang Lingyan, Zhong Lin, Gao Yi, Qiu Li. Multimodal ultrasound manifestations of port-wine stains and their application in efficacy assessment of photodynamic therapy [J]. Chinese Journal of Dermatology, 2024, 57(9): 801-806.
[3]	Zeng Yue, Shao Huihong, Lin Shiwen, Wen Rou, Zou Xianbiao. Application of a wearable teleconsultation device in diagnosis of common skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(9): 797-800.
[4]	He Lan, Ma Ling, Jiang Qian, Chen Liuqing, Chen Hongying. Analysis of dermoscopic and reflectance confocal microscopic characteristics of 57 cases of extragenital lichen sclerosus [J]. Chinese Journal of Dermatology, 2024, 57(9): 791-796.
[5]	Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829.
[6]	Combination of Traditional and Western Medicine Dermatology, Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on the application of reflectance confocal microscopy in common melanocytic skin tumors（2024） [J]. Chinese Journal of Dermatology, 2024, 57(9): 775-784.
[7]	Lu Qing, Liu Yanqiu, Liu Danping, Zou Yongyi, Yang Bicheng. Variation analysis and prenatal diagnosis in a pedigree with oculocutaneous albinism [J]. Chinese Journal of Dermatology, 2024, 57(9): 842-843.
[8]	Wang Ruixia, Qu Yanlei, Ai Wenjin, Yan Lin, Qu Caijie, Shi Tongxin. A case of nonbullous neutrophilic lupus erythematosus [J]. Chinese Journal of Dermatology, 2024, 57(9): 832-834.
[9]	Wei-Qi REN Ya-Ru ZOU Min PAN. Risk factors for secondary infection in patients with bullous pemphigoid [J]. Chinese Journal of Dermatology, 2024, 57(8): 770-772.
[10]	Xie yuanyuan, Liu Yuzhen, Zeng Rong, . Application of skin imaging techniques in acne vulgaris [J]. Chinese Journal of Dermatology, 2024, 57(8): 757-760.
[11]	Luo Li, Zhang Bona, Wu Wei, Tang Wenjing, Li Yuehua, Liu Xiaoli, Ma Yanan, Li Cuicui, Qi Mengyan, Sun Ni, Shi Qiong. Efficacy and safety of 308-nm excimer laser and 308-nm excimer lamp in the treatment of 194 children with vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(8): 721-727.
[12]	Liu Qingfeng, Liu Lian, Diao Ping, Li Xiaoxue, Zhang Ting, Chen Haotian, Liu Xu, Jiang Xian. Diagnosis and treatment of port-wine stains-associated syndromes [J]. Chinese Journal of Dermatology, 2024, 57(7): 656-660.
[13]	Chen Haotian, Liu Lian, Zhang Ting, Liu Qingfeng, Li Xiaoxue, Diao Ping, Jiang Xian. Port-wine stains: mechanisms underlying the development and progression [J]. Chinese Journal of Dermatology, 2024, 57(7): 661-664.
[14]	Diao Ping, Han Chenglong, Liu Lian, Zhou Hui, Li Erlong, Jiang Xian. Efficacy and influencing factors of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of adult patients with port-wine stains: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(7): 595-600.
[15]	Zhang Sheng, Wang Xiuwei, Chen Jianyou, Deng Wei, Zhang Haihua, Zhang Gaolei, Liu Xiaoyan, Su Wei. Efficacy of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of facial port-wine stains in 15 children with Sturge-Weber syndrome [J]. Chinese Journal of Dermatology, 2024, 57(7): 616-622.

Consensus on the diagnosis and treatment of vitiligo （2024 version）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［31］

Related Articles 15

Metrics

Comments

Recommended 10